Opinion|Videos|October 7, 2024

Addressing Gaps in CKD, T2D, and CVD Guidelines

Key Takeaways

  • Future guidelines may integrate emerging evidence and novel therapeutic strategies for CKD, T2D, and CVD management.
  • Personalized treatment plans considering the interplay between CKD, T2D, and CVD could be emphasized.
SHOW MORE

Key opinion leaders explore educational initiatives aimed at enhancing guideline adherence in cardiometabolic risk management, emphasizing effective tactics for improving health outcomes.

Video content above is prompted by the following:

  • How might future guideline updates address current gaps in the management of patients with CKD, T2D, and CVD?

This activity is supported by Boehringer Ingelheim Pharmaceuticals Inc. and Eli Lilly and Company who provided financial support for this program.


Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.


Latest CME

Brand Logo

259 Prospect Plains Rd, Bldg H
Monroe, NJ 08831

609-716-7777

© 2025 MJH Life Sciences®

All rights reserved.

Secondary Brand Logo